紫杉醇口服给药系统的研究进展  

Research Progress on Paclitaxel Oral Administration System

作　　者：赵丽娟 陈祥娥 杨敏 ZHAO Li-juan;CHEN Xiang-e;YANG Min(Department of Pharmacy,Linglong Yingcheng Hospital,Yantai 265400,China;School of Biological Science,Jining Medical University,Rizhao 276826,China;Department of Pharmaceutics,School of Pharmacy,Shandong University,Jinan 250012,China)

机构地区：[1]玲珑英诚医院药学部,山东烟台265400 [2]济宁医学院生物科学学院,山东日照276826 [3]山东大学药学院药剂教研室,山东济南250012

出　　处：《药物生物技术》2020年第2期169-172,共4页Pharmaceutical Biotechnology

基　　金：山东省自然科学基金(No.ZR2019PH063)。

摘　　要：紫杉醇是一种广谱高效抗肿瘤药物,目前临床上使用的仅为紫杉醇的注射剂,然而紫杉醇溶解度较低,传统的紫杉醇注射剂需要用聚氧乙烯蓖麻油和乙醇来增强其溶解性,容易引起过敏反应,需要提前给予糖皮质激素和抗组胺药物,这给患者带来了极大的不便。相比之下,口服给药更易被患者接受。通过查阅相关文献,对紫杉醇口服给药系统研究现状进行了综述。Paclitaxel(PTX)is a broad-spectrum and high-efficiency anti-tumor drug.Currently,only paclitaxel injection is used clinically.However,paclitaxel has low solubility.Traditional paclitaxel injection needs Cremophor-ELand ethanol to enhance its solubility and cause allergic reactions.It is necessary to give glucocorticoids and antihistamines in advance,which brings great inconvenience to patients.In contrast,oral administration is more acceptable to patients.This paper reviews the research status of paclitaxel oral administration system by consulting related literature.

关 键 词：紫杉醇 抗肿瘤 口服生物利用度 口服给药系统 

分 类 号：K979.1[历史地理—人文地理学]